Reporting guidelines for oncology research: Helping to maximise the impact of your research

British Journal of Cancer

Volumn 118, Issue 5, 2018, Pages 619-628

  Maccarthy, Angela ^a   Kirtley, Shona ^a   De Beyer, Jennifer A ^a   Altman, Douglas G ^a   Simera, Iveta ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RESEARCH; HUMAN; MEDICAL LITERATURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; REVIEW; SCIENTIST; MEDICAL RESEARCH; METHODOLOGY; ONCOLOGY; RESEARCH; STANDARDS;

BIOMEDICAL RESEARCH; GUIDELINES AS TOPIC; HUMANS; MEDICAL ONCOLOGY; RESEARCH DESIGN; RESEARCH REPORT;

EID: 85043253917     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2017.407     Document Type: Review

References (74)

1. Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, Chen MH, Choi BI, Baere T, Dodd GD, Dupuy DE, Gervais DA, Gianfelice D, Gillams AR, Lee Jr FT, Leen E, Lencioni R, Littrup PJ, Livraghi T, Lu DS, McGahan JP, Meloni MF, Nikolic B, Pereira PL, Liang P, Rhim H, Rose SC, Salem R, Sofocleous CT, Solomon SB, Soulen MC, Tanaka M, Vogl TJ, Wood BJ, Goldberg SN (2014) Image-guided tumor ablation: standardization of terminology and reporting criteria-A 10-year update. Radiology 273(1): 241-260
2. Akard LP, Wang YL (2011) Translating trial-based molecular monitoring into clinical practice: importance of international standards and practical considerations for community practitioners. Clin Lymphoma Myeloma Leuk 11(5): 385-395
3. Altwairgi AK, Alfakeeh AH, Hopman WM, Parulekar WR (2015) Quality of reporting of chemotherapy compliance in randomized controlled trials of breast cancer treatment. Jpn J Clin Oncol 45(6): 520-526
4. Altwairgi AK, Booth CM, Hopman WM, Baetz TD (2012) Discordance between conclusions stated in the abstract and conclusions in the article: analysis of published randomized controlled trials of systemic therapy in lung cancer. J Clin Oncol 30(28): 3552-3557
5. Arroz M, Came N, Lin P, Chen W, Yuan C, Lagoo A, Monreal M, Tute R, Vergilio JA, Rawstron AC, Paiva B (2016) Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry B Clin Cytom 90(1): 31-39
6. Bodemer N, Muller SM, Okan Y, Garcia-Retamero R, Neumeyer-Gromen A (2012) Do the media provide transparent health information? A crosscultural comparison of public information about the HPV vaccine. Vaccine 30(25): 3747-3756
7. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, Lijmer JG, Moher D, Rennie D, Vet HC, Kressel HY, Rifai N, Golub RM, Altman DG, Hooft L, Korevaar DA, Cohen JF (2015) STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. Radiology 277(3): 826-832
8. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, Aach J, Ansorge W, Ball CA, Causton HC, Gaasterland T, Glenisson P, Holstege FC, Kim IF, Markowitz V, Matese JC, Parkinson H, Robinson A, Sarkans U, Schulze-Kremer S, Stewart J, Taylor R, Vilo J, Vingron M (2001) Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 29(4): 365-371
9. Brown DB, Gould JE, Gervais DA, Goldberg SN, Murthy R, Millward SF, Rilling WS, Geschwind JF, Salem R, Vedantham S, Cardella JF, Soulen MC, Society of Interventional Radiology Technology Assessment Cthe International Working Group on Image-Guided Tumor A (2009) Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc Interv Radiol 20(7 Suppl): S425-S434
10. Burton A, Altman DG (2004) Missing covariate data within cancer prognostic studies: a review of current reporting and proposed guidelines. Br J Cancer 91(1): 4-8
11. Bylicki O, Gan HK, Joly F, Maillet D, You B, Peron J (2015) Poor patientreported outcomes reporting according to CONSORT guidelines in randomized clinical trials evaluating systemic cancer therapy. Ann Oncol 26(1): 231-237
12. Callstrom MR, York JD, Gaba RC, Gemmete JJ, Gervais DA, Millward SF, Brown DB, Dupuy D, Goldberg SN, Kundu S, Rose SC, Thomas JJ, Cardella JF, Technology Assessment Committee of Society of Interventional R (2009) Research reporting standards for image-guided ablation of bone and soft tissue tumors. J Vasc Interv Radiol 20(12): 1527-1540
13. Campana LG, Clover AJ, Valpione S, Quaglino P, Gehl J, Kunte C, Snoj M, Cemazar M, Rossi CR, Miklavcic D, Sersa G (2016) Recommendations for improving the quality of reporting clinical electrochemotherapy studies based on qualitative systematic review. Radiol Oncol 50(1): 1-13
14. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, Hrobjartsson A, Mann H, Dickersin K, Berlin JA, Dore CJ, Parulekar WR, Summerskill WS, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D (2013) SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med 158(3): 200-207
15. Chang S, Vogelbaum M, Lang FF, Haines S, Kunwar S, Chiocca EA, Olivi A, Quinones-Hinojosa A, Parsa A, Warnick R (2007) GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of surgically based therapeutic clinical trials. J Neurooncol 82(2): 211-220
16. Chang SM, Reynolds SL, Butowski N, Lamborn KR, Buckner JC, Kaplan RS, Bigner DD (2005) GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials. Neuro Oncol 7(4): 425-434
17. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Lowenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD (2003) Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21(24): 4642-4649
18. Clark TW, Millward SF, Gervais DA, Goldberg SN, Grassi CJ, Kinney TB, Phillips DA, Sacks D, Cardella JF, Technology Assessment Committee of the Society of Interventional R (2009) Reporting standards for percutaneous thermal ablation of renal cell carcinoma. J Vasc Interv Radiol 20(7 Suppl): S409-S416
19. Collins GS, Reitsma JB, Altman DG, Moons KG (2015) Transparent reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med 162(1): 55-63
20. Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, Falk R, Wells K, Solomon A, Wechalekar A, Zonder J, Dispenzieri A, Gertz M, Streicher H, Skinner M, Kyle RA, Merlini G (2012) Consensus guidelines for the conduct and reporting of clinical trials in systemic lightchain amyloidosis. Leukemia 26(11): 2317-2325
21. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Lowenberg B, Bloomfield CD (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115(3): 453-474
22. Duff JM, Leather H, Walden EO, LaPlant KD, George TJ Jr (2010) Adequacy of published oncology randomized controlled trials to provide therapeutic details needed for clinical application. J Natl Cancer Inst 102(10): 702-705
23. Duffis EJ, Gandhi CD, Prestigiacomo CJ, Abruzzo T, Albuquerque F, Bulsara KR, Derdeyn CP, Fraser JF, Hirsch JA, Hussain MS, Do HM, Jayaraman MV, Meyers PM, Narayanan S (2012) Head, neck, and brain tumor embolization guidelines. J Neurointerv Surg 4(4): 251-255
24. Fumagalli D, Bedard PL, Nahleh Z, Michiels S, Sotiriou C, Loi S, Sparano JA, Ellis M, Hylton N, Zujewski JA, Hudis C, Esserman L, Piccart M (2012) A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. Lancet Oncol 13(6): e240-e248
25. Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D (2014) The CARE guidelines: consensus-based clinical case report guideline development. J Clin Epidemiol 67(1): 46-51
26. Glasziou P, Altman DG, Bossuyt P, Boutron I, Clarke M, Julious S, Michie S, Moher D, Wager E (2014) Reducing waste from incomplete or unusable reports of biomedical research. Lancet 383(9913): 267-276
27. Goodman SN, Fanelli D, Ioannidis JP (2016) What does research reproducibility mean? Sci Transl Med 8(341): 341ps12
28. Guilhot J, Baccarani M, Clark RE, Cervantes F, Guilhot F, Hochhaus A, Kulikov S, Mayer J, Petzer AL, Rosti G, Rousselot P, Saglio G, Saussele S, Simonsson B, Steegmann JL, Zaritskey A, Hehlmann R (2012) Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. Blood 119(25): 5963-5971
29. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E (2013) Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMC Med 11: 80
30. Jackson A, Marks LB, Bentzen SM, Eisbruch A, Yorke ED, Haken RK, Constine LS, Deasy JO (2010) The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome. Int J Radiat Oncol Biol Phys 76(3 Suppl): S155-S160
31. Jankova L, Dent OF, Molloy MP, Chan C, Chapuis PH, Howell VM, Clarke SJ (2015) Reporting in studies of protein biomarkers of prognosis in colorectal cancer in relation to the REMARK guidelines. Proteomics Clin Appl 9(11-12): 1078-1086
32. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG (2012) Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. Osteoarthritis Cartilage 20(4): 256-260
33. Kyzas PA, Denaxa-Kyza D, Ioannidis JP (2007) Quality of reporting of cancer prognostic marker studies: association with reported prognostic effect. J Natl Cancer Inst 99(3): 236-243
34. Lee CW, Chi KN (2000) The standard of reporting of health-related quality of life in clinical cancer trials. J Clin Epidemiol 53(5): 451-458
35. Levine D, Kressel HY (2016) 2016: reviewing for radiology-reporting guidelines and why we use them. Radiology 280(3): 659-662
36. Maillet D, Blay JY, You B, Rachdi A, Gan HK, Peron J (2016) The reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC members. Ann Oncol 27(1): 192-198
37. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93(4): 387-391
38. Meghelli L, Narducci F, Mariette C, Piessen G, Vanseymortier M, Leblanc E, Collinet P, Duhamel A, Penel N (2016) Reporting adverse events in cancer surgery randomized trials: a systematic review of published trials in oesophago-gastric and gynecological cancer patients. Crit Rev Oncol Hematol 104: 108-114
39. Messiou C, Bonvalot S, Gronchi A, Vanel D, Meyer M, Robinson P, Morosi C, Bloem JL, Terrier PH, Lazar A, Pechoux C, Wardelman E, Winfield JM, Boulet B, Bovee J, Haas RL (2016) Evaluation of response after pre-operative radiotherapy in soft tissue sarcomas; the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) and Imaging Group recommendations for radiological examination and reporting with an emphasis on magnetic resonance imaging. Eur J Cancer 56: 37-44
40. Meyer E, Delaney M, Lin Y, Morris A, Pavenski K, Tinmouth A, Murphy M, Slichter SJ, Heddle N, Dumont LJ (2013) A reporting guideline for clinical platelet transfusion studies from the BEST Collaborative. Transfusion 53(6): 1328-1334
41. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1): 207-214
42. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62(10): 1006-1012
43. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4: 1
44. Moorcraft SY, Marriott C, Peckitt C, Cunningham D, Chau I, Starling N, Watkins D, Rao S (2016) Patients' willingness to participate in clinical trials and their views on aspects of cancer research: results of a prospective patient survey. Trials 17: 17
45. Moore CM, Giganti F, Albertsen P, Allen C, Bangma C, Briganti A, Carroll P, Haider M, Kasivisvanathan V, Kirkham A, Klotz L, Ouzzane A, Padhani AR, Panebianco V, Pinto P, Puech P, Rannikko A, Renard-Penna R, Touijera K, Turkbey B, van Poppel H, Valdagni R, Walz J, Schoots I (2017) Reporting magnetic resonance imaging in men on active surveillance for prostate cancer: the PRECISE recommendations-A report of a European School of Oncology Task Force. Eur Urol 71(4): 648-655
46. Nahum AM (1979) Biting the bullet: minimum standards for reporting cancer treatment statistics. Head Neck Surg 1(3): 201
47. O'Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA (2014) Standards for reporting qualitative research: a synthesis of recommendations. Acad Med 89(9): 1245-1251
48. Ogrinc G, Davies L, Goodman D, Batalden P, Davidoff F, Stevens D (2016) SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process. BMJ Qual Saf 25(12): 986-992
49. Padhani AR, Lecouvet FE, Tunariu N, Koh DM, Keyzer F, Collins DJ, Sala E, Schlemmer HP, Petralia G, Vargas HA, Fanti S, Tombal HB, Bono J (2017) METastasis reporting and data system for prostate cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer. Eur Urol 71(1): 81-92
50. Papathanasiou AA, Zintzaras E (2010) Assessing the quality of reporting of observational studies in cancer. Ann Epidemiol 20(1): 67-73
51. Peron J, Maillet D, Gan HK, Chen EX, You B (2013) Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review. J Clin Oncol 31(31): 3957-3963
52. Peron J, Pond GR, Gan HK, Chen EX, Almufti R, Maillet D, You B (2012) Quality of reporting of modern randomized controlled trials in medical oncology: a systematic review. J Natl Cancer Inst 104(13): 982-989
53. Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Boughey J, Curigliano G, Dixon JM, Esserman L, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Symmans WF (2015) Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. Mod Pathol 28(9): 1185-1201
54. Radvany MG, Murphy KJ, Millward SF, Barr JD, Clark TW, Halin NJ, Kinney TB, Kundu S, Sacks D, Wallace MJ, Cardella JF, Technology Assessment Committee of the Society of Interventional R (2009) Research reporting standards for percutaneous vertebral augmentation. J Vasc Interv Radiol 20(10): 1279-1286
55. Raghav KP, Mahajan S, Yao JC, Hobbs BP, Berry DA, Pentz RD, Tam A, Hong WK, Ellis LM, Abbruzzese J, Overman MJ (2015) From protocols to publications: a study in selective reporting of outcomes in randomized trials in oncology. J Clin Oncol 33(31): 3583-3590
56. Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, Blade J, Richardson P, Orlowski R, Siegel D, Jagannath S, Facon T, Avet-Loiseau H, Lonial S, Palumbo A, Zonder J, Ludwig H, Vesole D, Sezer O, Munshi NC, San Miguel J (2011) Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 117(18): 4691-4695
57. Reeve BB, McFatrich M, Pinheiro LC, Weaver MS, Sung L, Withycombe JS, Baker JN, Mack JW, Waldron MK, Gibson D, Tomlinson D, Freyer DR, Mowbray C, Jacobs S, Palma D, Martens CE, Gold SH, Jackson KD, Hinds PS (2017) Eliciting the child's voice in adverse event reporting in oncology trials: Cognitive interview findings from the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events initiative. Pediatr Blood Cancer 64(3): e26261
58. Rubino M, Pragnell MVC (1999) Guidelines for reporting case series of tumours of the colon and rectum. Tech Coloproctol 3(2): 93-97
59. Salem R, Lewandowski RJ, Gates VL, Nutting CW, Murthy R, Rose SC, Soulen MC, Geschwind JF, Kulik L, Kim YH, Spreafico C, Maccauro M, Bester L, Brown DB, Ryu RK, Sze DY, Rilling WS, Sato KT, Sangro B, Bilbao JI, Jakobs TF, Ezziddin S, Kulkarni S, Kulkarni A, Liu DM, Valenti D, Hilgard P, Antoch G, Muller SP, Alsuhaibani H, Mulcahy MF, Burrel M, Real MI, Spies S, Esmail AA, Raoul JL, Garin E, Johnson MS, Benson AB, Sharma RA, Wasan H, Lambert B, Memon K, Kennedy AS, Riaz A, Technology Assessment C, Interventional Oncology Task Force of the Society of Interventional R (2011) Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol 22(3): 265-278
60. Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR (2004) Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 22(3): 537-556
61. Schulz KF, Altman DG, Moher D (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 152(11): 726-732
62. Sekula P, Pressler JB, Sauerbrei W, Goebell PJ, Schmitz-Drager BJ (2016) Assessment of the extent of unpublished studies in prognostic factor research: a systematic review of p53 immunohistochemistry in bladder cancer as an example. BMJ open 6(8): e009972
63. Sivendran S, Galsky MD (2016) Adverse event reporting in oncology clinical trials-lost in translation? Expert Opin Drug Saf 15(7): 893-896
64. Slemc L, Kunej T (2016) Transcription factor HIF1A: downstream targets, associated pathways, polymorphic hypoxia response element (HRE) sites, and initiative for standardization of reporting in scientific literature. Tumour Biol 37(11): 14851-14861
65. Stiles CR, Biondo PD, Cummings G, Hagen NA (2010) Clinical trials focusing on cancer pain educational interventions: core components to include during planning and reporting. J Pain Symptom Manage 40(2): 301-308
66. Stout NK, Knudsen AB, Kong CY, McMahon PM, Gazelle GS (2009) Calibration methods used in cancer simulation models and suggested reporting guidelines. Pharmacoeconomics 27(7): 533-545
67. Subramanian J, Simon R (2010) Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst 102(7): 464-474
68. Tam VC, Tannock IF, Massey C, Rauw J, Krzyzanowska MK (2011) Compendium of unpublished phase III trials in oncology: characteristics and impact on clinical practice. J Clin Oncol 29(23): 3133-3139
69. Tong A, Sainsbury P, Craig J (2007) Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care 19(6): 349-357
70. Unknown (1979) WHO Handbook for Reporting Results of Cancer treatment. WHO Handbook for Reporting Results of Cancer treatment Offset publication No.48
71. Vera-Badillo FE, Napoleone M, Krzyzanowska MK, Alibhai SM, Chan AW, Ocana A, Seruga B, Templeton AJ, Amir E, Tannock IF (2016) Bias in reporting of randomised clinical trials in oncology. Eur J Cancer 61: 29-35
72. Vickers AJ, Ballen V, Scher HI (2007) Setting the bar in phase II trials: the use of historical data for determining 'go/no go' decision for definitive phase III testing. Clin Cancer Res 13(3): 972-976
73. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP (2007) Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 335(7624): 806-808
74. Wendler JJ, Fischbach K, Ricke J, Jurgens J, Fischbach F, Kollermann J, Porsch M, Baumunk D, Schostak M, Liehr UB, Pech M (2016) Irreversible Electroporation (IRE): standardization of terminology and reporting criteria for analysis and comparison. Pol J Radiol 81: 54-64